AUTHORIZED AS A PHARMACEUTICAL COMPANY BY FRENCH REGULATORY AUTHORITIES (ANSM), CREAPHARM BIOSERVICES EXPANDS ITS SCOPE TO INCLUDE ADVANCED THERAPY MEDICINAL PRODUCTS
On the occasion of its third aniversary, the biobank which integrated CREAPHARM GROUP as
CREAPHARM BIOSERVICES, got its Manufacturer’s Authorisation from the French National Agency for Medicines and Health Products (ANSM*) on August 21th 2023.
The French-speaking Diabetes Society is seeking the expertise of three leaders in the French biobanking ecosystem to accelerate the identification of new factors associated with major cardiovascular events (MACE*) in patients.
*(major adverse cardiovascular events)
CREAPHARM BIOSERVICES has recently invested in -80°C nitrogen tanks to provide Biotechs and Research key players with a new solution to meet the challenges of ultra-low temperature storage.
CREAPHARM BIOSERVICES announces its investment in -80°C nitrogen tanks to provide the European
ultra-low temperature storage market with unparalleled performance.